Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Esperion Therapeutics's revenue per share for the
three
months ended in Mar. 2026 was $0.32.
Esperion Therapeutics's revenue per share for the trailing twelve months (TTM) ended in Mar. 2026 was $1.88.
Warning Sign:
Esperion Therapeutics Inc revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue Per Share Growth Rate of Esperion Therapeutics was 40.40% per year.
During the past 3 years, the average Revenue Per Share Growth Rate was 19.50% per year.
During the past 5 years, the average Revenue Per Share Growth Rate was -21.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for Esperion Therapeutics's Revenue per Share or its related term are showing as below:
ESPR'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -48.5 Med: -27 Max: 19.5
Current: 19.5
During the past 13 years, Esperion Therapeutics's highest 3-Year average Revenue Per Share Growth Rate was 19.50% per year. The lowest was -48.50% per year. And the median was -27.00% per year.
ESPR's 3-Year Revenue Growth Rate is ranked better than 87.15% of 903
companies
in the Drug Manufacturers industry
Industry Median: 3.8
vs ESPR: 19.50
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Esperion Therapeutics Revenue per Share Related Terms
Esperion Therapeutics Revenue per Share Historical Data
* Premium members only.
The historical data trend for Esperion Therapeutics's Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ESPR vs AMPH, NIKA, BIOA: Revenue per Share Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Esperion Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Esperion Therapeutics PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Esperion Therapeutics's PS Ratio distribution charts can be found below:
* The bar in red indicates where Esperion Therapeutics's PS Ratio falls into.
Esperion Therapeutics Revenue per Share Calculation
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Esperion Therapeutics's Revenue Per Share for the fiscal year that ended in Dec. 2025 is calculated as
Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.88
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Esperion Therapeutics (ESPR) has a Revenue per Share of $1.88 as of Mar. 2026. Revenue per share equals the per-share value of a company's sales. View historical data on Esperion Therapeutics and its competitors. According to the industry distribution chart, Esperion Therapeutics ranks #116 out of 903 companies in the Drug Manufacturers industry, placing it in the top 12.8%.
Is Esperion Therapeutics' Revenue per Share too high?
Esperion Therapeutics' current Revenue per Share is $1.88. The Drug Manufacturers industry median Revenue per Share is 3.80. Esperion Therapeutics' value of $1.88 is 50.5% below this industry median. Based on the distribution chart, Esperion Therapeutics ranks #116 out of 903 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Esperion Therapeutics has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Esperion Therapeutics' Revenue per Share compare to AMPH and NIKA?
According to the Drug Manufacturers industry distribution chart, Esperion Therapeutics ranks #116 out of 903 companies for Revenue per Share. This places Esperion Therapeutics in the top 13% of its industry — outperforming the majority of peers. The industry median Revenue per Share is 3.80. Esperion Therapeutics' value of $1.88 is 50.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue per Share for a Drug Manufacturers company?
The median Revenue per Share among Drug Manufacturers companies is 3.80, based on 903 companies in the industry. Companies in the top quartile (top 25%) have a Revenue per Share significantly above this median, while those in the bottom quartile fall well below. However, Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Esperion Therapeutics's current Revenue per Share of $1.88 is 50.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue per Share mean?
A high Revenue per Share can signal that a stock is expensive relative to its fundamentals. Revenue per share equals the per-share value of a company's sales. View historical data on Esperion Therapeutics and its competitors. For the Drug Manufacturers industry, the median Revenue per Share is 3.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Esperion Therapeutics's current Revenue per Share is $1.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Esperion Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Esperion Therapeutics (ESPR) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.28, compared to a current price of $3.18 — trading 39.5% above its estimated fair value. The current Revenue per Share is $1.88 and 50.5% below the Drug Manufacturers industry median of 3.80. Esperion Therapeutics' overall GF Score™ is 41/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue per Share calculated?
Revenue per Share is calculated from a company's financial statements. For Esperion Therapeutics (ESPR), the current Revenue per Share is $1.88 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Esperion Therapeutics (ESPR) Overvalued in 2026?
Based on GuruFocus' analysis, Esperion Therapeutics stock appears to be overvalued.
The current stock price of $3.18 is trading 39.5% above its estimated GF Value™ of $2.28.
GuruFocus considers Esperion Therapeutics to be Significantly Overvalued.
Key valuation signals for ESPR:
Revenue per Share: $1.88
GF Value™: $2.28 vs. price of $3.18 (39.5% above fair value)
Industry Position: 50.5% below the Drug Manufacturers median (#116 of 903)
No single metric tells the full story. See the ESPR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.
41GF Score
Get the complete analysis for ESPR
Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ESPR has been successfully added to your 
